Corcept Therapeutics Incorporated (NASDAQ: CORT) will present new data from its Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab-paclitaxel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE